Nerses Ghahramanyan
Research Subjects
Research Interests
Nerses Ghahramanyan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Araksya Vanoyan
Department of Adult Hematology, Yeolyan Hematology and Oncology Center, Yerevan, Armenia
1 shared publication - Artem Oganesyan
Department of Hematology and Transfusion Medicine, National Institute of Health, Yerevan, Armenia
1 shared publication - Eli Daniel Ehrenpreis
Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
1 shared publication Lusine Harutyunyan
Department of Adult Hematology, Yeolyan Hematology and Oncology Center, Yerevan, Armenia
1 shared publication- Maria Badikyan
Immune Oncology Research Institute, Yerevan, Armenia
1 shared publication - Mark Gregory
Wayne State University School of Medicine, Detroit, USA
1 shared publication
Latest Publications
- 31 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (8) , 1-11
Tolerability and safety of a new oral device for prevention and treatment of oral mucositis in patients with hematologic malignancies undergoing chemotherapy
Purpose Around 40% of patients undergoing systemic chemotherapy develop oral mucositis (OM), a major cause of morbidity in cancer patients. There are only a few options for preventing and treating OM. This study examines the tolerability of a novel oral device (Bocaliner™), designed to enhance the effects of oral topical therapies, in patients with hematologic malignancies receiving chemotherapy. Methods Data from phase 1/phase 2 randomized controlled trial SPOM (Study for the Prevention of Oral Mucositis) was analyzed. Patients from the Yeolyan Hematology and Oncology Center (Yerevan, Armenia) were randomized into two groups: benzydamine or saline mouthwash. Half of the patients in each study group were randomly assigned to Bocaliner™. Tolerability and safety questionnaires on days 1 and 14 of chemotherapy were completed. Results Twenty-eight patients (mean age of 49 years; 50% female) received oral devices and completed the study. On the tryout of the device, 22 (78.6%) patients reported tolerating it well, and six (21.4%) reported some discomfort. After 14 days, 15 patients (35.7%) reported benefit from the use, with six (21.4%) of patients stating the device helped to reduce pain, four (14.3%) indicating that it helped them to eat, and five (17.8%) claiming both. Adverse events included discomfort (n = 2, 7.1%), pain around the cheekbone (n = 3, 10.7%), nausea (n = 2, 7.1%), and increased salivation (n = 1, 3.6%); none of these led to discontinuation of the use. Eighteen (64%) participants said they would use the device again. OM developed in five patients (17.8%). Conclusions The use of a new medical device designed to enhance oral topical medications in combination with oral topical therapy is well tolerated among patients with hematologic malignancies on chemotherapy. Trial registration. ClinicalTrials.gov registry ID: NCT05338398 (Date of registry: April 15, 2022).
- 31 July 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (8) , 1-11
Tolerability and safety of a new oral device for prevention and treatment of oral mucositis in patients with hematologic malignancies undergoing chemotherapy
Purpose Around 40% of patients undergoing systemic chemotherapy develop oral mucositis (OM), a major cause of morbidity in cancer patients. There are only a few options for preventing and treating OM. This study examines the tolerability of a novel oral device (Bocaliner™), designed to enhance the effects of oral topical therapies, in patients with hematologic malignancies receiving chemotherapy. Methods Data from phase 1/phase 2 randomized controlled trial SPOM (Study for the Prevention of Oral Mucositis) was analyzed. Patients from the Yeolyan Hematology and Oncology Center (Yerevan, Armenia) were randomized into two groups: benzydamine or saline mouthwash. Half of the patients in each study group were randomly assigned to Bocaliner™. Tolerability and safety questionnaires on days 1 and 14 of chemotherapy were completed. Results Twenty-eight patients (mean age of 49 years; 50% female) received oral devices and completed the study. On the tryout of the device, 22 (78.6%) patients reported tolerating it well, and six (21.4%) reported some discomfort. After 14 days, 15 patients (35.7%) reported benefit from the use, with six (21.4%) of patients stating the device helped to reduce pain, four (14.3%) indicating that it helped them to eat, and five (17.8%) claiming both. Adverse events included discomfort (n = 2, 7.1%), pain around the cheekbone (n = 3, 10.7%), nausea (n = 2, 7.1%), and increased salivation (n = 1, 3.6%); none of these led to discontinuation of the use. Eighteen (64%) participants said they would use the device again. OM developed in five patients (17.8%). Conclusions The use of a new medical device designed to enhance oral topical medications in combination with oral topical therapy is well tolerated among patients with hematologic malignancies on chemotherapy. Trial registration. ClinicalTrials.gov registry ID: NCT05338398 (Date of registry: April 15, 2022).